Please assess the completion status of the following clinical trial:

Trial Title: A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants ages 2-15 years~* Documented detrusor overactivity associated with a known neurological condition such as meningomyelocele or spinal cord injury, and confirmed by urodynamics at baseline~* Using clean intermittent catheterization (CIC) on a regular basis~* Participating in a bowel program on a regular basis~* Able to swallow the study medication in accordance to the protocol~* Participants and/or parent/guardian able to complete the bladder diary and follow the study procedures~Exclusion Criteria:~* Treatment with drugs known to significantly affect the urinary bladder and urinary bladder outlet function~* Fecal impaction. Participants may be included, once this condition has resolved~* Clinically significant anatomical abnormalities or acquired disorders of the urinary tract~* Previous reconstructive surgery (augmentation etc.) of the bladder or bladder outlet~* Symptomatic urinary tract infection unresolved at time of urodynamic study and/or completion of bladder diary.~* Diabetes insipidus~* Electro stimulation therapy or bladder training within 2 weeks prior to Visit 1 and at any time during the study~* Concomitant diseases, in which the use of darifenacin is contraindicated~* History of hypersensitivity to darifenacin or to drugs with similar chemical structures~* Participants with any physical and cognitive impairment or any other condition which in the opinion of the investigator makes the participants unsuitable for inclusion~* Female adolescent of child-bearing potential, unless using an acceptable method of contraception~* Pregnant or nursing (lactating) female adolescents Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Darifenacin 0.030 mg/kg/day) (Type: EXPERIMENTAL): Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.030 milligrams/kilogram/day (mg/kg/day) dispensed per twice a day (BID) dosing, for 14 days.
- Cohort 2 (Darifenacin 0.0625 mg/kg/day) (Type: EXPERIMENTAL): Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.0625 mg/kg/day dispensed per BID dosing, for 14 days.
- Cohort 3 (Darifenacin 0.125 mg/kg/day) (Type: EXPERIMENTAL): Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.125 mg/kg/day dispensed per BID dosing, for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).